THAC, The Healthy Aging Company, is a French and US-based privately-owned biopharmaceutical company which has the ambition to develop a range of first-in-class drug candidates targeting T2DM and its complications.
THAC aims to change the way patient care and healthy aging are addressed. THAC is primarily focused on Type 2 Diabetes Mellitus (incl. prevention of complications), a condition with still unmet medical needs, as identified by health agencies.
♦ Its pipeline could lead to potential real game changers for patient care and disease management. THAC is primarily focused on Type 2 Diabetes Mellitus, a condition with still unmet medical needs.
♦ THAC envisions that by fighting insulin resistance, the root cause of T2DM, major breakthrough could be achieved for the treatment of T2DM and the prevention of severe related complications such as peripheral neuropathy (e.g. diabetic foot wounds, amputations).
♦ THAC drug candidates have a unique and innovative mechanism of action that targets oxidation and inflammation, which restores the composition of microbiota, and the insulin sensitivity.
♦ THAC drug candidates are intended to delay disease progression, improve patient’s quality of life, delay premature death and prevent T2DM complications ; peripheral neuropathy is a severe complication for which there is no treatment available; e.g., diabetic foot wounds and amputations.
ALF-5755, the active ingredent of THAC drug candidates for T2DM, is targeted the root cause of the disease by tackle the apperance of insulin resistance all along the disease, and by acting directly to the gut microbiota in order to restore the dysbiosis.
Thanks to its unique and innovative properties against local inflammation and local oxidation, ALF-5755 is also able to decrease and to prevent side effects and complications related to T2DM and age-related diseases.
Existing marketed drugs are focused on the consequences of T2DM and induces side-effects and complications
Despite the recent progress in existing therapeutic solutions, the main classes of marketed drugs are targeting the consequences of the disease. They mainly aim to decrease the accumulated concentration of the glucose in the blood by acting on the liver, the pancreas, the kidney etc. But they do not directly address the cause of the accumulation of the blood glucose.
Severe complications can be induced by these marketed drugs: pancreatitits, heart failure, severe glycemic desequilibrium, lactic acidosis, renal dysfunction etc.
Futhermore, there is no marketed drug which act on the gut microbiota despite the latest scientific discoveries showing a direct link between dysbiosis and T2DM.
T2DM is the first non-infectious pandemics in the world and the first killer (WHO)
♦ Despite existing therapeutic solutions, Type 2 diabetes is a chronic age-related disease which will concern up to 750 millions patients by 2040 (+51% from 2019). One adult out of 10 will be affected by the disease by mid-century. The quality of life of the patient is highly degraded, their life expectancy is reduced up to 10 years with severe complications, and the disease is responsible of one death every 6 seconds in the world.
♦ Amongst the severe complications, the diabetic foot wound is considered as a medical urgency with a drastic evolution towards foor ulcers and amputation. Up to 25% of the diabetic patients is concerned. Due to the fact that there is no adapted prevention and treatment, one lower limb amputation is observed every 30 seconds in the world, in the context of the T2DM.
♦ T2DM is also an economic burden on patients and healthcare machinery around the globe. The market is going to be doubled between 2016-2026 and the total available market including pre-diabetes is reaching several hundreds of million dollars. Worldwide associated costs are expected to reach around £1000 bn in 2045. Additionnal costs related to the severe complications have to be included. – Ceed diabetes 2020, Diabetologica 2020, J Epid Global Health 2019.
Therapeutic progress in T2DM has been achieved with 4 main classes of products, usually prescribed in bi- and tri-therapies, and based on different modes of action for controlling glycemia. But despite these therapeutic achievements, T2DM has still an ineluctable evolution in most patients. The adaptation of the treatment is mandatory all along the progression of the disease. the death of patients is still pre-matured, and severe complications of the disease are not prevented. In that context, WHO and international diabetes associations claimed the need of new drugs which present the following features (WHO T2DM Global Report).
♦ Delayed disease progression (disease modifier)
♦ Better balance between efficacy on glycemia control and safety
♦ Higher glycemai control in the long term
♦ Reduced and prevented costly burden of diabetic complications
♦ Must address the insulin resistance as this is the root cause of the disease while offering a strong safety profile
American Diabetes Association and European Association of Diabetes, aligned with WHO recommend to target insulin resistance, the root cause of T2DM.
Insulin resistance starts early in life, is silent and asymptomatic for many years, may lead to severe complications and can cause premature deat
ALF-5755, the active ingredient of THAC drug candidates, is able to tackle insulin resistance, the root cause of T2DM and its complications, due to its unique and innovation mechanism of action which is well descripbed and patented.
THAC envisions that by fighting insulin resistance, the root cause of T2DM, with its drug candidates having a unique and innovative mechanism of action targeting oxidation and inflammation, a major breakthrough could be achieved for the treatment of T2DM and the prevention of severe related complications such as peripheral neuropathy (e.g. diabetic foot wounds, amputations), in response to the unmet medical need.
The drug candidates are ready to enter into clinical phase II after being GMP produced, and first in man injected with a successul safety profile in humans.